Valuation: Zymeworks Inc.

Market Cap 2.03B 1.74B 1.63B 1.49B 2.8B 195B 2.84B 19.26B 7.51B 97.78B 7.64B 7.47B 323B P/E 2026 *
20.2x
P/E 2027 * 37.8x
Enterprise Value 2.03B 1.74B 1.63B 1.49B 2.8B 195B 2.84B 19.26B 7.51B 97.78B 7.64B 7.47B 323B EV / Sales 2026 *
6.54x
EV / Sales 2027 * 5.63x
Free-Float
92.08%
Yield 2026 *
-
Yield 2027 * -
1 day+7.90%
1 week+14.13%
Current month+30.67%
1 month+22.73%
3 months+11.95%
6 months+26.19%
Current year+8.89%
1 week 24.94
Extreme 24.94
28.74
1 month 21.52
Extreme 21.52
28.74
Current year 21.52
Extreme 21.52
29.75
1 year 13.6
Extreme 13.6
29.75
3 years 6.02
Extreme 6.015
29.75
5 years 4.11
Extreme 4.11
37.19
10 years 4.11
Extreme 4.11
59.03
Manager TitleAgeSince
Chief Executive Officer 63 2022-01-04
Director of Finance/CFO 44 2026-03-31
Chief Tech/Sci/R&D Officer - 2024-11-30
Director TitleAgeSince
Chairman 63 2022-01-04
Director/Board Member 61 2019-05-31
Director/Board Member 52 2020-02-29
Date Insider Type Main position Quantity % Market Cap.
7/6/26 Free

Chief Operating Officer

939 0.0013%
2/1/26 Other

Chief Technology Officer

272,000 0.3635%
1/12/26 Free

Director

19,200 0.0257%
Change 5-day change 1-year change 3-year change Capi.($)
+7.90%+14.13%+89.87%+264.76% 2.03B
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.92%+8.94%+62.17%+204.39% 29.15B
Weighted average by Cap. +0.79%+9.51%+58.25%+158.60%

Financials

2026 *2027 *
Net sales 311M 266M 249M 228M 428M 29.75B 434M 2.94B 1.15B 14.95B 1.17B 1.14B 49.43B 361M 309M 289M 265M 497M 34.55B 504M 3.42B 1.33B 17.36B 1.36B 1.33B 57.41B
Net income 120M 103M 95.95M 87.83M 165M 11.45B 167M 1.13B 442M 5.75B 450M 440M 19.03B 86.88M 74.42M 69.64M 63.74M 120M 8.31B 121M 823M 321M 4.18B 326M 319M 13.81B
Net Debt - -
Logo Zymeworks Inc.
Zymeworks Inc. is a biotechnology company. The Company is engaged in managing a portfolio of healthcare assets and developing a pipeline of multifunctional biotherapeutics to improve the standard of care for conditions, including cancer, inflammation, and autoimmune disease. Its antibody-drug conjugates (ADCs) include ZW191, ZW251, and ZW220. ZW191 is a clinical-stage ADC that targets folate receptor alpha-expressing tumors including ovarian cancer, endometrial cancer, and non-small cell lung cancer (NSCLC), which is built using bystander-active, TOPO1i payload technology, ZD06519. ZW251 is a clinical-stage ADC molecule designed for the treatment of glypican 3 (GPC3)-expressing hepatocellular carcinoma (HCC). ZW220 is an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer, built using bystander active TOPO1i payload technology, ZD06519. Its therapeutic platforms can be used to develop multifunctional fit-for-purpose biotherapeutics with bispecific capabilities.
Employees
231
Date Price Change Volume
26-08-21 US$28.67 +7.90% 836,383
26-08-20 US$26.57 -2.35% 498,746
26-08-19 US$27.21 +4.37% 845,210
26-08-18 US$26.07 +3.00% 650,165
26-08-17 US$25.31 +0.76% 442,399
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.67USD
Average target price
40.33USD
Spread / Average Target
+40.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ZYME Stock